Background Women with twin pregnancy are at high risk for spontaneous preterm delivery. Progesterone seems to be eff ective in reducing preterm birth in selected high-risk singleton pregnancies, albeit with no signifi cant reduction in perinatal mortality and little evidence of neonatal benefi t. We investigated the use of progesterone for prevention of preterm birth in twin pregnancy.
Introduction
Multiple pregnancies accounted for 1·6% of all births in the UK during 2007, 1,2 with more than 98% of these multiple births being twin births. 2 Rates of stillbirth and neonatal mortality for multiple pregnancies are 14·9 and 19·8 per 1000 livebirths, respectively, and are three to eight times higher than for singleton pregnancies. 3 The economic costs of health-care provision in the fi rst 5 years of life are twice as high per child after twin birth compared with singleton birth. 4 Prematurity continues to be the major cause of neonatal death in multiple births, with preterm labour potentially the most treatable cause of prematurity. 3 In the long term, the morbidity in both singleton and multiple survivors of preterm birth is well documented, and is known to lead to poor health and reduced achievement both in school and in adulthood. 5 Such morbidity is associated with major fi nancial costs to the health service, and with personal suff ering to the individuals and their families.
No eff ective interventions have been shown to prevent preterm delivery in twin pregnancy. By contrast, three large randomised trials [6] [7] [8] have suggested that progesterone might prevent preterm delivery in high-risk singleton pregnancy. The likelihood of preterm birth in women with singleton pregnancy who are identifi ed at risk of preterm delivery because of either a previous preterm delivery 6, 7 or a short cervix 8 might be reduced by antenatal progesterone. Importantly, evidence that a reduction in the rate of preterm birth is accompanied by neonatal benefi t is scarce because there is no reduction in perinatal mortality, and risk of neonatal sepsis is the only secondary neonatal outcome that is reduced in babies of women with singleton pregnancy treated with antenatal progesterone. 9 The STOPPIT study (STudy Of Progesterone for the Prevention of Preterm Birth In Twins) was designed to test the hypothesis that the occurrence of delivery or intrauterine death before 34 weeks and 0 days of gestation would be lower in women with twin pregnancy randomly assigned to progesterone gel than in those randomly assigned to matching placebo.
with multiple pregnancy at nine UK National Health Service hospitals. All women with a twin pregnancy, with gestation and chorionicity established by scan before 20 weeks' gestation, and attending the antenatal clinic during the recruitment period were eligible for recruitment. Women were not eligible if their pregnancy was complicated by a recognised structural or chromosomal fetal abnormality at the time of recruitment, or if they had contraindications to progesterone, planned cervical suture, planned elective delivery before 34 weeks' gestation, or planned intervention for twin-to-twin transfusion before 22 weeks' gestation. Women with higher multiple pregnancy were also excluded.
Participants gave written informed consent, and the study was granted approval by the West Glasgow Ethics Committee 1 (reference 04/S0703/13).
Procedures
We aimed to recruit and randomly assign women at 22 weeks' gestation. When possible, the project was discussed with women at booking, and again at 22 weeks' gestation. All women had at least 1 week to decide whether to participate. Participants were randomly assigned to either daily progesterone gel (90 mg; Crinone [Serono, Feltham, Middlesex, UK]) or to placebo gel administered vaginally by the participant and starting at 24 weeks and 0 days of gestation. Drugs were supplied in a sealed opaque covering. Every cover contained a single-use, one piece, white polyethylene applicator with a twist-off top, designed for intravaginal self-insertion. Each applicator contained 1·45 g of gel and delivered 1·125 g of gel, containing either 8% progesterone or excipients (glycerin, light liquid paraffi n, hydrogenated palm oil glyceride, carbopol 974P, sorbic acid, polycarbophil, sodium hydroxide, and purifi ed water).
We used a randomisation schedule with permuted blocks of randomly mixed sizes to make up treatment packs (either active or placebo) for every patient, which were held in individual hospital pharmacies until use. On recruitment, the local researcher (usually a midwife) telephoned the interactive voice response randomisation application at the UK Clinical Research Network registered trials unit (The Centre for Healthcare Randomised Trials [CHaRT] , in the Health Services Research Unit, University of Aberdeen, UK), to be given a participant number that corresponded to a specifi c treatment pack. We used a minimisation algorithm incorporating hospital and chorionicity to assign participants to the randomised treatment group.
All study personnel and participants were masked to treatment assignment for the duration of the study. Only the study statistician and the independent Data Monitoring Committee had access to unblinded data, but none had any contact with study participants.
Outcomes
The primary outcome was delivery or intrauterine death before 34 weeks and 0 days of gestation. We used delivery of the fi rst twin to defi ne the time of delivery. If one twin died in utero before 34 weeks and the other was born alive after 34 weeks, intrauterine fetal death was defi ned as occurring before 34 weeks. The gestational age was calculated from ultrasound scan done before 20 weeks. The maternal secondary outcomes were gestation at delivery, method of delivery (spontaneous vaginal delivery, vaginal breech, forceps or ventouse, or caesarean section), duration of each stage of labour, and safety outcomes such as duration of stay in hospital. Neonatal secondary outcomes were neonatal unit admission and duration of neonatal unit care. We also ascertained maternal satisfaction by questionnaire. Women were followed up from randomisation until they gave birth. Outcomes were recorded from the hospital notes, and entered into a web-based data capture system by a trained clinician, usually a study midwife.
Statistical analysis
The proportion of deliveries before 34 weeks' gestation in twin pregnancy is about 20% (Chalmers J, Information Services Division, NHS Scotland, Edinburgh, UK, personal communication). Our study size of 250 women per group gave 85% power at 5% signifi cance level to show a reduction in the rate of preterm delivery or intrauterine death before 34 weeks' gestation from 20% to 10% in the active treatment group and was based on a conservative estimate of likely eff ect size derived from previous studies. 6 Analysis was done by intention to treat and followed a prespecifi ed statistical analysis plan. For the primary outcome, the odds ratio (OR) of the treatment eff ect, adjusting for the minimisation covariate (chorionicity), was estimated with a 95% CI, and associated likelihood ratio p value with logistic regression. We also undertook a predefi ned subgroup analysis of the primary outcome by monochorionicity (yes or no). We analysed continuous maternal secondary outcomes with normal linear regression models, adjusting for chorionicity. Treatment eff ects, 95% CIs, and p values were calculated as described in the statistical analysis plan. We analysed binary categorical secondary outcomes with logistic regression as per the primary outcome. For data with multiple categories (eg, method of delivery), we compared the two randomised groups with a proportional odds model.
Fetal outcomes allowed for the clustering within twins. Analyses were as for the maternal outcomes, except with the addition of mother as a random eff ect in the linear and logistic regression models. No missing data were imputed. No adjustment was made for any multiple comparisons. An independent Data Monitoring Committee met regularly throughout the study. No formal interim analyses were under taken, and so no adjustment was made. All statistic al analyses were undertaken in SPSS for Windows (version 17.0.0) and Stata (version 10.1).
The trial was registered on EUDRAct, number 2004-000780-10, and as an International Standard Randomised Controlled Trial, number ISRCTN35782581.
Meta-analysis
We did an electronic search of the published medical literature (PubMed and Cochrane Controlled Trials Register) for studies in which women with twin pregnancy were randomly allocated to treatment with a progestogen (including progesterone, 17-hydroxyprogesterone caproate) or placebo in the second or third trimester with the intention to prevent preterm birth. We used the search terms "preterm birth" AND ["progesterone" OR "17 hydroxyprogesterone caproate" OR "progestogen"] AND ["pregnancy multiple" OR "pregnancy twin"] AND "randomised controlled trial" AND "human". We considered all published randomised controlled trials in which progestogens were given to women with twin pregnancy for the prevention of preterm birth. We excluded those in which progestogens were given to women with symptoms of preterm labour, or in which data were available in abstract form only. Two reviewers (J E Norman and J Norrie) reviewed identifi ed papers for relevance and quality, and abstracted the data. Published studies were assessed for quality according to Jadad's quality assessment scale. 10 Our prespecifi ed primary outcomes were the incidence of delivery or intrauterine fetal death before 34 weeks' gestation. When data for our primary outcome of interest were not available in the published report, we contacted the relevant chief investigator to obtain the required information. We calculated ORs and 95% CIs for the primary outcome.
Role of the funding source
Neither the funder nor the supplier of active and placebo drugs had any role in study design, data collection, data analysis, data interpretation, or writing of the report. The joint study sponsor in terms of the EU Clinical Directive had no role in analysis of data. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le. Participants attended clinic visits at the time of randomisation (baseline) and at intervals during pregnancy, and were admitted to the study hospital for delivery and postnatal care. Table 1 shows the baseline demographics and clinical characteristics of the participants. Three women in each of the progesterone and the placebo groups were lost to follow-up (because of withdrawal of consent or not traceable after moving out of study area); thus data from 494 patients were available for the intention-to-treat analysis of the primary outcome. No patients were con -sidered protocol violators, and none were unblinded before ascertainment of all outcomes. Thus 494 mothers and 988 babies remained for the per-protocol analyses.
Results
The proportion of women delivering or with an intrauterine death before 34 weeks was 61/247 (24·7%) in the progesterone group and 48/247 (19·4%) in the placebo group (OR 1·36 [95% CI 0·89-2·09], p=0·16; table 2). Thus, by contrast with our original hypothesis, progesterone did not reduce the incidence of preterm delivery or intrauterine death before 34 weeks' gestation. Subgroup analysis of the primary outcome by chorionicity suggested an increase in the rate of preterm delivery or intrauterine death before 34 weeks in association with progesterone in women with dichorionic pregnancies (table 2) . However, the p value for the formal test of interaction between the monochorionic and dichorionic groups was not signifi cant (p=0·056), implying that the response to treatment in the monochorionic and dichorionic groups did not diff er signifi cantly. Thus the fi nding of increased rates of adverse outcomes in the dichorionic group should be interpreted with suitable caution. Tables 3 and 4 show secondary maternal outcomes,  table 5 neonatal outcomes, table 6 safety issues, table 7 side-eff ects, and table 8 maternal satisfaction. The only apparent diff erences between the groups were reduced odds of caesarean (OR 0·53, 95% CI 0·34-0·84; p=0·006), operative vaginal delivery (OR 0·42, 0·21-0·83; p=0·013), and nausea (OR 0·43, 0·20-0·94; p=0·035) in the progesterone group. The rate of adverse events did not diff er between the two groups (table 6).
136 women in the progesterone group and 151 women in the placebo group returned diaries indicating that they had taken 80% or more of their medication. The remainder either did not return their diary or stopped early because of preterm delivery, because they were told to stop, or because they were incompletely compliant with treatment.
Electronic searching of published work generated 198 results relevant for meta-analysis. Review of the abstracts indicated that only two studies fulfi lled the inclusion criteria. Relevant data could be abstracted from one of these papers. 11 In view of the discrepancy between the published primary outcome (spontaneous preterm delivery before 34 weeks' gestation) and the outcome we planned for the meta-analysis (intrauterine death or any preterm delivery before 34 weeks' gestation) we contacted the senior author of the other paper 8 who supplied the relevant data. A further paper 12 was not found on electronic searching, but was brought to the attention of the authors and considered for inclusion. This paper showed that the These data refer to all twins, both the fi rst and second, with 95% CIs and p values adjusted for clustering among the twin set. *Data are event (%) for admission to neonatal unit, and mean (SD) for duration of neonatal unit stay. †Data are odds ratio (95% CI) for progesterone versus placebo for admission to neonatal unit, and mean diff erence (95% CI) for duration of neonatal unit stay. primary outcome (spontaneous preterm delivery before 37 completed weeks of gestation) was again diff erent from the one that we planned in the meta-analysis, and because the paper was published in 1980, we decided that contacting the author for further information would not be helpful. Both trials included in the meta-analysis were rated as of highest quality according to the Jadad score. 10 The pooled OR of the eff ect of progesterone in preterm delivery or intrauterine death before 34 weeks' gestation was 1·16 (95% CI 0·89-1·51; fi gure 2).
Discussion
We have shown that progesterone did not reduce the composite outcome of risk of delivery or intrauterine death before 34 weeks of pregnancy in women with twin pregnancy. Our results accord with the other large published trial 11 in twin pregnancy that used 17-hydroxyprogesterone caproate (250 mg) given intramuscularly from 16-20 to 35 weeks, and with the most recent meta-analysis on this issue. 9 The relative risk of preterm birth or intrauterine death before 35 weeks in the 655 women available for analysis was 1·1 (95% CI 0·9-1·3) in the active compared with the placebo group.
11
Our study has the following strengths. It was a double-blind, placebo-controlled trial with central randomisation, and it had a prespecifi ed sample size that was achieved, a prespecifi ed primary endpoint and analysis plan that was followed, and a high rate of follow-up. Loss to follow-up for the primary outcome was small. Our exclusion criteria were few, and thus more than four-fi fths of women with twin pregnancy were eligible for the study.
Potential limitations of our study are that the uptake of the study in eligible participants was less than we initially anticipated, with only 40% (500/1249) of eligible women agreeing to participate, and that the study was largely undertaken in tertiary referral centres. These issues could have aff ected the external validity of our trial. The overall rate of preterm delivery or intrauterine death before 34 weeks was 22% (109/494), which is similar to another (singleton) study in which progesterone was shown to be eff ective. 6 The dose of vaginal progesterone was similar to the dose used in that singleton study, 6 although less than that in another. 8 The dose we used is at the lower end of proven eff ective doses, but meta-analyses have not shown a dose-response eff ect. 13 We therefore believe that the dose of progesterone we used was unlikely to have been too small.
Our unexpected observation of overall lower rates of both caesarean section and operative vaginal delivery in the progesterone group should be interpreted with caution. We noted no eff ect on any other labour parameters and no signifi cant eff ect when we analysed pre-labour and post-labour caesarean sections separately. The eff ect on caesarean delivery was not detected in other large studies using progesterone during twin pregnancy (relative risk 1·0, 95% CI 0·9-1·1) 11 or singleton pregnancy (0·94, 0·68-1·30). 7 Progesterone is unlikely to have reduced caesarean section by improving fetal wellbeing, in view of the trend towards increased perinatal mortality that we recorded (14 deaths in the progesterone group vs ten in the placebo group). Furthermore, progesterone was unlikely to have improved uterine contractility during labour since it is known to have a relaxant, rather than a stimulatory, eff ect on the Data shown are any reported symptom at either of the 6-week or the 10-week visits, without adjustment for the baseline measure. uterus. 14 Because reduction in caesarean section is one of several secondary outcomes in our study, and because of the absence of biological plausibility and no confi rmation from other studies, we believe that this fi nding is most likely to be one of chance.
The clinical implication of our study is that progestogens are not eff ective in women with twin pregnancy for prevention of preterm delivery. Although six further clinical trials of the eff ect of 17-hydroxyprogesterone caproate or progesterone in the prevention of preterm delivery in twin pregnancy are ongoing-two large trials (registration numbers NCT00329914 [with a planned sample size of 750] and ISRCTN40512715 [with a planned sample size of 660]) and four smaller trials (NCT00343265, NCT00480402, NCT00141908, and NCT 00163020, with a combined planned sample size of 957)-unless their combined eff ect size is large with an odds ratio of 0·65 or less, they will not change the overall conclusion of this and the previous 11 study that progesterone is ineff ective.
Our results contrast with the randomised trials and meta-analyses of high-risk singleton pregnancies in which progesterone seems to be eff ective in reducing preterm birth, although this reduction will only be clinically useful if accompanied by long-term improvement in the health of off spring. At present, there is no evidence to suggest that this is the case. This issue is being specifi cally addressed in singletons in a randomised trial of progesterone, with infant function at 2-3 years of age as our primary outcome (OPPTIMUM study, registration number ISRCTN14568373). The biological mechanism by which preterm delivery occurs might be diff erent in twin and singleton pregnancy, and this hypothesis merits further study. Perhaps stretching of uterine muscle has a substantial role in preterm labour in twin pregnancy, and infection and infl ammation a role in singletons. We did not recruit women with higher multiple pregnancy (eg, triplets), but a recent publication did not show any eff ect of progesterone in prevention of preterm birth in triplet pregnancy. Overall, how satisfi ed were you with participating in the STOPPIT study? (1=very satisfi ed; 10=completely dissatisfi ed)
2·5 (2·2) 2·1 (1·6) 0·4 (-0·1 to 0·8) 0·093
Data are mean (SD) over two visits (at weeks 6 and 10), adjusted for the baseline measure. 
